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Renal effects of telmisartan, 
ramipril, or both in patients with 
heart or end-stage renal disease
Angiotensin receptor blockers (ARBs) and angiotensin-converting 
enzyme (ACE) inhibitors are known to reduce proteinuria. Their 
combination may be more effective than either treatment alone, 
but long-term data for comparative changes in renal function are 
not available. Mann et al. investigated the renal effects of ramipril 
(an ACE inhibitor), telmisartan (an ARB), and their combination 
in patients aged 55 years or older with established atherosclerotic 
vascular disease or diabetes and end-stage renal disease. In the 
six-year, multicenter, double-blind, controlled trial, 25,620 partici-
pants were randomly assigned to ramipril 10 mg per day, telmisar-
tan 80 mg per day, or a combination of both drugs. During the 
median follow-up of 56 months, renal function and proteinuria 
were measured. The primary renal outcome was a composite of 
dialysis, doubling of serum creatinine, and death. The number of 
adverse events for the composite primary outcome was similar for 
telmisartan and ramipril but increased with combination therapy 
(P = 0.037). The secondary renal outcome, dialysis or doubling of 
serum creatinine, was similar with telmisartan and ramipril and 
more frequent with combination therapy (P = 0.038). Estimated 
glomerular filtration rate declined less with ramipril than with 
telmisartan (P < 0.0001) or combination therapy (P < 0.0001). The 
increase in urinary albumin excretion was less with telmisartan 
(P = 0.004) or combination therapy (P = 0.001) than with rami-
pril. In people at high vascular risk, telmisartan and ramipril had 
similar effects on major renal outcomes. Although combination 
therapy reduced proteinuria more than monotherapy, it worsened 
major renal outcomes. (Lancet 2008; 372: 547–553; doi:10.1016/
S0140-6736(08)61236-2)
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Tumor necrosis factor-α promotes 
polycystic kidney disease
It has been proposed that cyst generation in autosomal domi-
nant polycystic kidney disease (ADPKD) results from germline 
inactivation of a single allele of either PKD1 or PKD2 (genes 
that encode polycystin-1 and polycystin-2, respectively) plus 
clonal expansion of tubule epithelial cells that acquire a ‘sec-
ond hit’ mutation that inactivates the second, functional copy 
of the gene. However, in mice with a hypomorphic Pkd1 allele, 
reduction in Pkd1 expression was found to be sufficient to ini-
tiate cystogenesis. Further, the high frequency at which cysts 
develop in human ADPKD suggests that nongenetic factors may 
also contribute to cyst formation. One of the possible physi-
ological factors is the proinflammatory cytokine tumor necrosis 
factor-α (TNF-α), as TNF-α mRNA and protein are markedly 
increased after hypertensive stress and renal injury, conditions 
that are associated with ADPKD. In studies, TNF-α was found 
to increase progressively with age in cystic kidneys of congeni-
tal polycystic kidney (cpk) mice, a rodent model of autosomal 
recessive polycystic kidney disease (ARPKD), and was also 
present in human ADPKD cyst fluids. Li et al. investigated the 
relationship between TNF-α and ADPKD. They found that the 
cytokine disrupted the localization of polycystin-2 to the plasma 
membrane and primary cilia through a scaffold protein, FIP2, 
which was induced by TNF-α. Treating mouse embryonic kid-
ney organ cultures with TNF-α resulted in formation of cysts, 
which was exacerbated in the Pkd2+/– kidneys. TNF-α also 
stimulated cyst formation in vivo in Pkd2+/– mice. In contrast, 
the TNF-α inhibitor etanercept prevented cyst formation in 
Pkd2+/– mice (Figure). These data reveal a pathway connecting 
TNF-α signaling, polycystins, and cystogenesis, the activation 
of which may reduce functional polycystin-2 below a critical 
threshold, precipitating the ADPKD cellular phenotype. (Nat 
Med 2008; 14: 863–868; doi:10.1038/nm1783)
Juan Oliver
FGF-23 and mortality among CKD 
patients on hemodialysis
The relationship between increased phosphorus levels and 
mortality has long been established among chronic kidney 
disease (CKD) patients on hemodialysis. Prior studies have 
suggested that fibroblast growth factor 23 (FGF-23), fetuin A, 
and vitamin D levels may play a mechanistic role. FGF-23 is an 
important regulator of vitamin metabolism. In patients with 
CKD, secondary increases in FGF-23 levels stimulate greater 
excretion of phosphorus and limit the reabsorption of dietary 
phosphorus by inhibiting synthesis of 1,25-dihydroxyvitamin 
D. Gutiérrez et al. now hypothesize that FGF-23 may have an 
The TNF-α inhibitor etanercept prevents cyst formation in Pkd2+/– mice. 
Kidney histology sections from Pkd2+/– mice injected with etanercept 
(left) or calcium and magnesium (middle and right) are shown. For 
control examples (–Etanercept), the panel to the right of each kidney 
section shows an enlarged image of a cyst in that section.
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association with mortality. Their study examined FGF-23 levels 
among 10,044 subjects on dialysis. Patients who died during the 
first year of hemodialysis were more likely to have a lower serum 
albumin, lower serum creatinine, or higher serum ferritin lev-
els. Patients with higher FGF-23 levels were more likely to have 
higher serum creatinine, phosphate, and alkaline phosphatase 
levels (P<0.001). Increased FGF-23 levels were associated with 
significantly increased risk of death (odds ratio = 1.5, P<0.001) 
among all patients. When stratified on levels of serum phosphate, 
the risk of increased FGF-23 levels was stable in all groups except 
among those with serum phosphate greater than 5.5 mg/dl. In 
this group, the odds ratio was no longer significant; however, 
the P value was different from those of the other groups but not 
significant (0.26). When FGF-23 levels were adjusted for age, sex, 
race, blood pressure, weight, facility factors, laboratory values, 
and other processes of care, the relationship between FGF-23 and 
mortality became increasingly significant. African-American and 
Hispanic patients had a significant survival advantage compared 
with white patients (odds ratio = 0.5 and 0.4, respectively). The 
risk of death was similar for both African-American and white 
patients with FGF-23 levels above the median. However, for those 
with FGF-23 levels below the median, African Americans had a 
60% lower risk of death compared with white patients.
This study demonstrates an association between FGF-23 levels 
and mortality. FGF-23 could therefore represent a biomarker for 
patients at risk with lower serum phosphorus levels. Future stud-
ies need to demonstrate that treatments affecting serum phos-
phorus balance also impact FGF-23 levels, and that lowering its 
value in patients also lowers their risk of death. (N Engl J Med 
2008; 359: 584–592)
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Stimulation of lymphocytes by 
angiotensin II enhances kidney 
injury
The capacity of angiotensin II, acting via its AT1 receptor, to 
promote kidney injury is demonstrated by the efficacy of AT1 
receptor blockers (ARBs) in slowing the progression of CKD. It 
is well established that the ability of ARBs to ameliorate renal and 
cardiovascular disease depends, at least in part, on their blood 
pressure-lowering effects. But clinical trials suggest that the ben-
efits of ARBs cannot be explained by blood pressure reduction 
alone. One blood pressure-independent mechanism through 
which ARBs protect the kidney may involve direct inhibition of 
proinflammatory cellular actions of angiotensin II. For example, 
angiotensin causes lymphocyte proliferation, nuclear factor-κB 
activation, and generation of mononuclear-cell chemokines such 
as monocyte chemoattractant protein-1and the interleukin-8 
cytokine RANTES in the kidney. Further, in models of kidney 
allograft rejection, blockade of AT1 receptors in the transplant 
recipient improves survival and reduces histologic injury inde-
pendent of blood pressure control. Yet, a precise characteriza-
tion of angiotensin’s proinflammatory effects on the pathogenesis 
of hypertensive end-stage renal disease remains incomplete. 
The recent findings that suppression of lymphocytes or their 
deficiency changes blood pressure responses to angiotensin II 
further complicated this issue. To study the interaction of angi-
otensin II with lymphocytes and kidney damage, Crowley et al. 
induced hypertension and kidney disease by chronic infusion 
of angiotensin II in 129/SvEv mice. The immunosuppressive 
agent mycophenolate mofetil (MMF) had no effect on the sever-
ity of hypertension or cardiac hypertrophy, but it significantly 
reduced albuminuria and ameliorated kidney injury by decreas-
ing glomerulosclerosis and reducing lymphocyte infiltration into 
the renal interstitium (Figure). Attenuation of renal pathology 
with MMF was associated with reduced expression of mRNAs 
for the proinflammatory cytokines interferon-γ and tumor necro-
sis factor-α and the profibrotic cytokine transforming growth 
factor-β. In vitro experiments showed that angiotensin II caused 
rearrangement of the actin cytosk eleton of splenic lymphocytes, 
an action that required activation of Rho kinase. Hence, angi-
otensin II increased hypertensive kidney injury by stimulating 
lymphocyte responses. These proinflammatory actions of angi-
otensin II appeared to have a proclivity for inducing kidney injury 
while having negligible actions in the pathogenesis of cardiac 
hypertrophy. (Am J Physiol Renal Physiol 2008; 295: F515–F524; 
doi:10.1152/ajprenal.00527.2007)
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MMF treatment diminishes T-lymphocyte infiltration into the kidney 
during angiotensin II infusion. T cells stain brown. Representative kidney 
sections from control group (a), angiotensin II group (b), and angiotensin 
plus MMF (c).
